Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to $47.9 million.

  • Ascendis Pharma A's Net Cash Flow fell 8825.68% to $47.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.7 million, marking a year-over-year decrease of 14017.31%. This contributed to the annual value of $156.5 million for FY2024, which is 41945.73% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Net Cash Flow stood at $47.9 million, which was down 8825.68% from -$5.3 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Net Cash Flow ranged from a high of $407.7 million in Q3 2024 and a low of -$295.0 million during Q4 2021
  • In the last 5 years, Ascendis Pharma A's Net Cash Flow had a median value of -$68.0 million in 2024 and averaged -$5.1 million.
  • Data for Ascendis Pharma A's Net Cash Flow shows a peak YoY increase of 81662.5% (in 2024) and a maximum YoY decrease of 22229.88% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Net Cash Flow stood at -$295.0 million in 2021, then surged by 51.19% to -$144.0 million in 2022, then surged by 69.5% to -$43.9 million in 2023, then crashed by 112.79% to -$93.5 million in 2024, then skyrocketed by 151.23% to $47.9 million in 2025.
  • Its Net Cash Flow was $47.9 million in Q3 2025, compared to -$5.3 million in Q2 2025 and -$34.8 million in Q1 2025.